BrainStorm Cell Therapeutics Inc. (BCLI) is higher today on heavy volume after initiating efficacy and safety studies toward a cure for Amyelotrophic Lateral Sclerosis (ALS), Lou Gehrig's disease, a rare and incurable neurodegenerative disease characterized by rapid loss of motor neurons leading to impaired motor-function and progressive paralysis. As the disease progresses, the patient loses control of the muscles controlling speech, swallowing and finally breathing, which inevitably becomes fatal within 3-5 years from onset for the vast majority of patients. The cause of the disease is yet unknown.
BrainStorm's human neurotrophic factor (NTFs) producing cells from human bone marrow into transgenic mutant SOD mice (mice with mutated human genes and the most common animal model of the human disease). Preliminary results demonstrated a positive effect on the deteriorated motor function. BrainStorm's large-scale efficacy studies will provide additional data to support this initial pilot study.
Current treatment options use conventional medications that can only offer to alleviate ALS symptoms or slow the disease's progression, such as Rilutek(R)(riluzole). Lioresal(R)(baclofen) and Zanaflex(R)(tizanadine) may relieve spasticity. Ultram(R)(tramadol) is often prescribed for pain relief.
The Company is also focused on developing stem cell technologies that use the patient's own bone marrow to treat diseases such as Parkinson's Disease and Multiple Sclerosis. Bone marrow includes stem cells capable of differentiation into both hemopoeitic (blood and lymph) and mesenchymal (muscle, bone, fat and other) tissues. Bone marrow stem cells have even been shown capable of differentiating into nerve and skin cells.
Neurodegenerative diseases are increasing in prevalence and significantly raising heatlhcare costs. The U.S. constitutes the world's largest market for these products, with 40% of global sales. According to the World Health Organization, Neurodegenerative diseases will become the world's second leading cause of death by 2040, overtaking cancer.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
BrainStorm's human neurotrophic factor (NTFs) producing cells from human bone marrow into transgenic mutant SOD mice (mice with mutated human genes and the most common animal model of the human disease). Preliminary results demonstrated a positive effect on the deteriorated motor function. BrainStorm's large-scale efficacy studies will provide additional data to support this initial pilot study.
Current treatment options use conventional medications that can only offer to alleviate ALS symptoms or slow the disease's progression, such as Rilutek(R)(riluzole). Lioresal(R)(baclofen) and Zanaflex(R)(tizanadine) may relieve spasticity. Ultram(R)(tramadol) is often prescribed for pain relief.
The Company is also focused on developing stem cell technologies that use the patient's own bone marrow to treat diseases such as Parkinson's Disease and Multiple Sclerosis. Bone marrow includes stem cells capable of differentiation into both hemopoeitic (blood and lymph) and mesenchymal (muscle, bone, fat and other) tissues. Bone marrow stem cells have even been shown capable of differentiating into nerve and skin cells.
Neurodegenerative diseases are increasing in prevalence and significantly raising heatlhcare costs. The U.S. constitutes the world's largest market for these products, with 40% of global sales. According to the World Health Organization, Neurodegenerative diseases will become the world's second leading cause of death by 2040, overtaking cancer.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
